US Dollar vs Yen

ブラジル証券取引所、NASDAQ、NYSE、AMEX、LSEなどの主要取引所からの複数のリアルタイム株価を監視します。

登録

ホーム
投資
株式
アメリカ
NASDAQ
NewAmsterdam Pharma Company NV (NAMS)
NewAmsterdam Pharma Company NV (NAMS) ニュース

NAMS

NewAmsterdam Pharma Comp... (NAMS)

NewAmsterdam Pharma Company NV

から:

Regulatory News

Text Search:

次の項目別のソート:

Non-Regulatory News

Showing the most relevant articles for your search:NASDAQ:NAMS

日付	受信時刻	ニュースソース	見出し	コード	企業名
2024/05/21	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present New Clinical and Preclinical Data Highlighting Obicetrapib’s Impact on Key Risk Factors for Cardiovascular Disease at Upcoming Medical Meetings	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/05/09	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/05/04	05 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/05/02	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Host R&D Day with Key Opinion Leaders on May 16, 2024	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/04/09	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Enrolls Over 9,000 Patients in Pivotal Phase 3 PREVAIL Global Cardiovascular Outcome Trial Evaluating the Effect of Obicetrapib in Patients with Established Atherosclerotic Cardiovascular Disease	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/04/01	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces the Appointment of Juliette Audet as Chief Business Officer	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/03/25	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present New Analysis from the Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe at 2024 American College of Cardiology Congress	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/03/12	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Doses First Patient in Phase 3 TANDEM Clinical Trial Evaluating Fixed-Dose Combination of Obicetrapib and Ezetimibe in Patients with HeFH and/or ASCVD	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/02/28	22 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Reports Full Year 2023 Financial Results and Provides Corporate Update	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/02/26	22 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Participate in Upcoming Investor Conferences in March	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/02/14	12 : 40	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Pricing of $175.3 Million Public Offering of Ordinary Shares and Pre-Funded Warrants	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/02/14	06 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Commencement of Public Offering of Ordinary Shares and Pre-Funded Warrants	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/02/02	06 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma to Present at Guggenheim Healthcare Talks 6th Annual Biotechnology Conference	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/01/08	22 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Appoints William H. Lewis, J.D., M.B.A. as Chair of its Board of Directors	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2024/01/04	22 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces 2024 Strategic Priorities	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/11/13	22 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter 2023 Financial Highlights	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/10/23	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Appointment of Ian Somaiya as Chief Financial Officer	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/09/21	20 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Initial Data from Phase 2a Clinical Trial Evaluating Obicetrapib in Patients with Early Alzheimer’s Disease Who Carry an ApoE4 Mutation	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/09/20	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present at 2023 Cantor Fitzgerald Global Healthcare Conference	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/08/15	05 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Appointment of William “BJ” Jones, formerly of Biohaven Pharmaceuticals, as Chief Commercial Officer	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/08/07	20 : 15	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter 2023 Financial Highlights	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/07/26	05 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Completes Enrollment in Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia and/or Established Atherosclerotic Cardiovascular Disease	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/06/10	05 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Closing of Upsized Secondary Offering of Ordinary Shares	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/06/07	12 : 25	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Pricing of Upsized Secondary Offering of Ordinary Shares	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/06/07	05 : 01	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Commencement of Secondary Offering of Ordinary Shares	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/06/05	20 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Announces Positive Topline Results from Phase 2b Dose-Finding Trial Evaluating Obicetrapib in Japanese Patients	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/06/04	01 : 15	GlobeNewswire Inc.	NewAmsterdam Pharma Presents Full Data from Phase 2 ROSE2 Trial Evaluating Obicetrapib in Combination with Ezetimibe as an Adjunct to High-Intensity Statin Therapy at NLA Scientific Sessions 2023	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/05/31	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma to Present at Jefferies Healthcare Conference	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/05/23	21 : 00	GlobeNewswire Inc.	NewAmsterdam to Present Full Data from ROSE2 at NLA Scientific Sessions 2023	NASDAQ:NAMS	NewAmsterdam Pharma Company NV
2023/05/08	21 : 00	GlobeNewswire Inc.	NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Highlights	NASDAQ:NAMS	NewAmsterdam Pharma Company NV

Showing the most relevant articles for your search:NASDAQ:NAMS

Invesco QQQ Trust Series 1

US Dollar vs Yen

BNP Paribas (QX)

Verizon Communications

US Dollar vs Euro

Bank of America

Gold vs US Dollar

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約